PRESS RELEASE 1
er
MAY 2024.
UPDATING THE COVERAGE OF THE PREDILIFE TITLE BY IN EXTENSO FINANCE;
PRICE OBJECTIVE OF €25.07 OR +391%
Villejuif, France, 1
er
May 2024 at 8:30 a.m. CET – PREDILIFE
(Euronext Growth: ALPRE FR0010169920), specialist in artificial intelligence methods for predicting the risks of pathologies for personalized medicine, announces the updating of its price target by In Extenso Finance, an investment bank dedicated to VSEs and SMEs growing.
In its annual note published on April 30, 2024, In Extenso Finance updates the monitoring of the Predilife stock with a strong buy recommendation with a price target of €25.07, representing an upside potential of 391% compared to the price. closing date for the action on April 29, 2024 of €5.10 (study available
here
).
The company pursues and strengthens the value of its intellectual property, thanks to its MammoRisk test
®
the risk model used in the European MyPeBS study, recruitment for which has just ended.
The research contract signed with In Extenso Financement & Marché is part of PREDILIFE’s desire to strengthen its stock market visibility among professional and individual investors.
About PREDILIFE
PREDILIFE is a pioneering company in the design and development of prediction tests intended to prevent major diseases. It uses artificial intelligence methods applied to clinical and genetic medical data within a secure legal framework. Predicting these individual risks makes it possible to propose a personalized monitoring protocol and earlier identification of pathologies.
To find out more: www.predilife.com
|
Contacts PREDILIFE Investor Relations Stéphane Ragusa Chairman and CEO CAPVALUE Press Relations |
This publication has the “🔒 Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
xmtsZJRvl2yVmp6daMtnmGmWaWdlyJbGmZacmZVql8vIcHCWnZuXZsfKZnFmmmlm
– To control this key:
https://www.security-master-key.com.
Unregulated information:
Full and original press release in PDF format:
https://www.actusnews.com/news/85540-cp_actualisation-de-la-couverture-du-titre-predilife-par-in-extenso.pdf
© Copyright Actusnews Wire
Receive future company press releases free of charge by email by subscribing to www.actusnews.com